Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MRK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMerck closes $6 billion debt offering across seven note series with rates up to 5.85%
Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read
Key Changes
-
high
Merck raised $6 billion through seven debt tranches maturing between 2028 and 2056, with interest rates ranging from floating rate to 5.85% fixed, significantly increasing the company's debt obligations while providing substantial liquidity.
Item 8.01 verify on EDGAR → -
medium
The offering includes $500 million in floating rate notes and in fixed-rate notes, with longer maturities carrying higher rates (5.75% for 2046 notes, 5.85% for 2056 notes).
Item 8.01 verify on EDGAR → -
medium
The largest tranches are $1.5 billion in 2036 notes at 5.20% and $1 billion each in 2028, 2033, and 2056 notes, suggesting a balanced approach to maturity profile and interest rate exposure.
Item 8.01 verify on EDGAR →
Summary
Merck completed a substantial $6 billion debt offering on May 22, 2026, issuing seven separate note series with maturities spanning three decades. The offering includes one floating rate tranche and six fixed-rate tranches with coupons between 4.30% and 5.85%, reflecting current market conditions where longer-term debt commands higher yields.
The largest allocation is $1.5 billion in 10-year notes at 5.20%, with billion-dollar tranches also placed at the short end (2028) and long end (2056) of the maturity spectrum. For retail investors, this capital raise increases Merck's debt burden and future interest obligations, which will impact earnings and cash flow.
However, the staggered maturities reduce refinancing risk, and the proceeds likely support general corporate purposes, potential acquisitions, or R&D investments. The relatively high interest rates reflect the current rate environment and Merck's credit profile. Watch for Merck's next quarterly earnings call for management commentary on how these proceeds will be deployed—whether for strategic acquisitions, pipeline development, or balance sheet management. Also monitor the company's debt-to-equity ratio and interest coverage metrics in upcoming 10-Q filings.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Merck closed $6 billion debt offering across seven note series with maturities from 2028 to 2056.
Added in current filing · verify on EDGAR →
On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes”
Merck completed a $6 billion debt offering consisting of seven separate note series with varying interest rates and maturity dates. The offering includes one floating rate tranche and six fixed-rate tranches with coupons ranging from 4.300% to 5.850% and maturities spanning 2028 to 2056. This represents a significant capital raise that will increase the company's debt obligations but provides substantial liquidity for corporate purposes.
Event · Item 9.01 — Financial Statements and Exhibits
Merck issued seven series of notes totaling multiple maturities from 2028 to 2056, including floating rate and fixed rate debt.
Added in current filing · view on EDGAR →
Exhibit 4.1 Floating Rate Notes due 2028 Officers’ Certificate of the Company dated May 22, 2026, including form of the Floating Rate Notes. Exhibit 4.2 4.300% Notes due 2028 Officers’ Certificate of the Company dated May 22, 2026, including form of the 2028 Notes. Exhibit 4.3 4.650% Notes due 2031 Officers’ Certificate of the Company dated May 22, 2026, including form of the 2031 Notes. Exhibit 4.4 4.950% Notes due 2033 Officers’ Certificate of the Company dated May 22, 2026, including form of the 2033 Notes. Exhibit 4.5 5.200% Notes due 2036 Officers’ Certificate of the Company dated May 22, 2026, including form of the 2036 Notes. Exhibit 4.6 5.750% Notes due 2046 Officers’ Certificate of the Company dated May 22, 2026, including form of the 2046 Notes. Exhibit 4.7 5.850% Notes due 2056 Officers’ Certificate of the Company dated May 22, 2026, including form of the 2056 Notes.
Merck issued seven series of debt securities on May 22, 2026, with maturities ranging from 2028 to 2056. The offering includes one floating rate note series and six fixed rate series with coupons from 4.300% to 5.850%, with longer-dated notes carrying higher interest rates. This represents a significant debt capital raise across multiple maturity profiles, likely for general corporate purposes, refinancing, or strategic initiatives.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 22, 2026 · How we verify